

PHARMACY POLICY STATEMENT

Marketplace

DRUG NAME	Livmarli (maralixibat)
BENEFIT TYPE	Pharmacy
Coverage Requirements	Prior Authorization Required

Livmarli (maralixibat) is an ileal bile acid transport (IBAT) inhibitor initially approved by the FDA in 2021 for

8. Dosage allowed/Quantity limit: Starting dose is 190mcg/kg orally once daily, titrating up to 380 mcg/kg once daily. Max dose 28.5 mg (3 mL) per day. QL: 3 bottles (90 mL) per 30 days.

If all the above requirements are met , the medication will be approved for 6 months.

For reauthorization :

1. Pruritis has improved in response to therapy with Livmarli.

If all the above requirements are met, the medication will be approved for an additional 12 months.

CareSource considers Livmarli (maralixibat